In the case of PD-L1/PD-1 blockade therapy, the expression level of TMB, tumor-infiltrating lymphocytes, PD-L1, and mismatch repair deficiency can all influence ICI therapy (Wang et al., 2019; Touat et al., 2020). This evidence concerns the gene CD274 and mismatch repair cancer syndrome 1.